The selective metabotropic glutamate 2/3 receptor agonist MGS0028 reverses isolation rearing-induced abnormal behaviors in mice

Journal of Pharmacological Sciences

Volumn 118, Issue 2, 2012, Pages 295-298

  Ago, Yukio ^a   Araki, Ryota ^a   Yano, Koji ^a   Kawasaki, Toshiyuki ^b   Chaki, Shigeyuki ^c   Nakazato, Atsuro ^c   Onoe, Hirotaka ^b   Hashimoto, Hitoshi ^a   Baba, Akemichi ^a,d   Takuma, Kazuhiro ^a   Matsuda, Toshio ^a  

^a OSAKA UNIVERSITY   (Japan)

^b RIKEN   (Japan)

^c TAISHO PHARMACEUTICAL CO LTD   (Japan)

^d HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Behavior; Isolation rearing; Metabotropic glutamate 2 3 receptor

Indexed keywords

METABOTROPIC RECEPTOR 2 AGONIST; METABOTROPIC RECEPTOR 3 AGONIST; METABOTROPIC RECEPTOR AGONIST; MSG 0028; UNCLASSIFIED DRUG;

ABNORMAL BEHAVIOR; AGGRESSION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HYPERACTIVITY; LOCOMOTION; MALE; MOUSE; NONHUMAN; PREPULSE INHIBITION; RAT; STARTLE REFLEX;

EID: 84857604480     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.11200SC     Document Type: Article

References (16)

1. Chaki S. Group II metabotropic glutamate receptor agonists as a potential drug for schizophrenia. Eur J Pharmacol. 2010;639: 59-66.
2. Fone KC, Porkess MV. Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders. Neurosci Biobehav Rev. 2008;32:1087-1102.
3. Millan MJ, Brocco M, Gobert A, Schreiber R, Dekeyne A. S-16924 [(R)-2-[1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)- ethyl]-pyrrolidin-3yl]-1- (4-fluorophenyl)-ethanone], a novel, potential antipsychotic with marked serotonin1A agonist properties: III. Anxiolytic actions in comparison with clozapine and haloperidol. J Pharmacol Exp Ther. 1999;288:1002-1014. (Pubitemid 29254137)
4. Kawasaki T, Ago Y, Yano K, Araki R, Washida Y, Onoe H, et al. Increased binding of cortical and hippocampal group II metabotropic glutamate receptors in isolation-reared mice. Neuropharmacology. 2011;60:397-404.
5. Nakazato A, Kumagai T, Sakagami K, Yoshikawa R, Suzuki Y, Chaki S, et al. Synthesis, SARs, and pharmacological characterization of 2-amino-3 or 6-fluorobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivatives as potent, selective, and orally active group II metabotropic glutamate receptor agonists. J Med Chem. 2000;43:4893-4909. (Pubitemid 32002702)
6. Ago Y, Araki R, Yano K, Hiramatsu N, Kawasaki T, Chaki S, et al. Activation of metabotropic glutamate 2/3 receptors attenuates methamphetamine-induced hyperlocomotion and increase in prefrontal serotonergic neurotransmission. Psychopharmacology (Berl). 2011;217:443-452.
7. Sakaue M, Ago Y, Sowa C, Sakamoto Y, Nishihara B, Koyama Y, et al. Modulation by 5-HT2A receptors of aggressive behavior in isolated mice. Jpn J Pharmacol. 2002;89:89-92. (Pubitemid 34618614)
8. Ago Y, Koda K, Takuma K, Matsuda T. Pharmacological aspects of the acetylcholinesterase inhibitor galantamine. J Pharmacol Sci. 2011;116:6-17.
9. Moghaddam B, Adams BW. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science. 1998;281:1349-1352. (Pubitemid 28406826)
10. Swanson CJ, Schoepp DD. A role for noradrenergic transmission in the actions of phencyclidine and the antipsychotic and antistress effects of mGlu2/3 receptor agonists. Ann N Y Acad Sci. 2003;1003:309-317. (Pubitemid 38083064)
11. Marek GJ, Wright RA, Schoepp DD, Monn JA, Aghajanian GK. Physiological antagonism between 5-hydroxytryptamine2A and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther. 2000;292:76-87. (Pubitemid 30026356)
12. González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, López-Giménez JF, et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature. 2008;452: 93-97. (Pubitemid 351355090)
13. Jones CA, Brown AM, Auer DP, Fone KC. The mGluR2/3 agonist LY379268 reverses post-weaning social isolation-induced recognition memory deficits in the rat. Psychopharmacology (Berl). 2011;214:269-283.
14. Ossowska K, Pietraszek M, Wardas J, Nowak G, Zajaczkowski W, Wolfarth S, et al. The role of glutamate receptors in antipsychotic drug action. Amino Acids. 2000;19:87-94.
15. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007;13:1102-1107. (Pubitemid 47517511)
16. Kinon BJ, Zhang L, Millen BA, Osuntokun OO, Williams JE, Kollack-Walker S, et al. A multicenter, inpatient, phase 2, doubleblind, placebo-controlled dose-ranging study of LY2140023 monohydrate in patients with DSM-IV schizophrenia. J Clin Psychopharmacol. 2011;31:349-355.